BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35372904)

  • 1. Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020.
    Gupta S; Cortazar FB; Riella LV; Leaf DE
    Kidney360; 2020 Feb; 1(2):130-140. PubMed ID: 35372904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
    Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis.
    Kanbay M; Yildiz AB; Siriopol D; Vehbi S; Hasbal NB; Kesgin YE; Celayir M; Selcukbiricik F; Covic A; Perazella MA
    Int Urol Nephrol; 2023 Apr; 55(4):1025-1032. PubMed ID: 36282399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute kidney injury in patients treated with immune checkpoint inhibitors.
    Gupta S; Short SAP; Sise ME; Prosek JM; Madhavan SM; Soler MJ; Ostermann M; Herrmann SM; Abudayyeh A; Anand S; Glezerman I; Motwani SS; Murakami N; Wanchoo R; Ortiz-Melo DI; Rashidi A; Sprangers B; Aggarwal V; Malik AB; Loew S; Carlos CA; Chang WT; Beckerman P; Mithani Z; Shah CV; Renaghan AD; Seigneux S; Campedel L; Kitchlu A; Shin DS; Rangarajan S; Deshpande P; Coppock G; Eijgelsheim M; Seethapathy H; Lee MD; Strohbehn IA; Owen DH; Husain M; Garcia-Carro C; Bermejo S; Lumlertgul N; Seylanova N; Flanders L; Isik B; Mamlouk O; Lin JS; Garcia P; Kaghazchi A; Khanin Y; Kansal SK; Wauters E; Chandra S; Schmidt-Ott KM; Hsu RK; Tio MC; Sarvode Mothi S; Singh H; Schrag D; Jhaveri KD; Reynolds KL; Cortazar FB; Leaf DE;
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors and acute kidney injury.
    Zhou P; Gao Y; Kong Z; Wang J; Si S; Han W; Li J; Lv Z; Wang R
    Front Immunol; 2024; 15():1353339. PubMed ID: 38464524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study.
    Lumlertgul N; Vassallo P; Tydeman F; Lewis N; Hobill A; Weerapolchai K; Nordin NZ; Seylanova N; Martin L; Cennamo A; Wang Y; Rigg A; Shaunak N; Ostermann M
    Eur J Cancer; 2023 Sep; 191():112967. PubMed ID: 37499561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study.
    Shimamura Y; Watanabe S; Maeda T; Abe K; Ogawa Y; Takizawa H
    Clin Exp Nephrol; 2021 May; 25(5):479-487. PubMed ID: 33471239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.
    Manohar S; Ghamrawi R; Chengappa M; Goksu BNB; Kottschade L; Finnes H; Dronca R; Leventakos K; Herrmann J; Herrmann SM
    Kidney360; 2020 Jan; 1(1):16-24. PubMed ID: 35372854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI.
    Gupta S; Garcia-Carro C; Prosek JM; Glezerman I; Herrmann SM; Garcia P; Abudayyeh A; Lumlertgul N; Malik AB; Loew S; Beckerman P; Renaghan AD; Carlos CA; Rashidi A; Mithani Z; Deshpande P; Rangarajan S; Shah CV; Seigneux S; Campedel L; Kitchlu A; Shin DS; Coppock G; Ortiz-Melo DI; Sprangers B; Aggarwal V; Benesova K; Wanchoo R; Murakami N; Cortazar FB; Reynolds KL; Sise ME; Soler MJ; Leaf DE;
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36137651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach.
    Yu X; Wu R; Ji Y; Huang M; Feng Z
    Diagnostics (Basel); 2022 Dec; 12(12):. PubMed ID: 36553164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
    Cortazar FB; Kibbelaar ZA; Glezerman IG; Abudayyeh A; Mamlouk O; Motwani SS; Murakami N; Herrmann SM; Manohar S; Shirali AC; Kitchlu A; Shirazian S; Assal A; Vijayan A; Renaghan AD; Ortiz-Melo DI; Rangarajan S; Malik AB; Hogan JJ; Dinh AR; Shin DS; Marrone KA; Mithani Z; Johnson DB; Hosseini A; Uprety D; Sharma S; Gupta S; Reynolds KL; Sise ME; Leaf DE
    J Am Soc Nephrol; 2020 Feb; 31(2):435-446. PubMed ID: 31896554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
    Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
    Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
    Cortazar FB; Marrone KA; Troxell ML; Ralto KM; Hoenig MP; Brahmer JR; Le DT; Lipson EJ; Glezerman IG; Wolchok J; Cornell LD; Feldman P; Stokes MB; Zapata SA; Hodi FS; Ott PA; Yamashita M; Leaf DE
    Kidney Int; 2016 Sep; 90(3):638-47. PubMed ID: 27282937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
    Seethapathy H; Zhao S; Chute DF; Zubiri L; Oppong Y; Strohbehn I; Cortazar FB; Leaf DE; Mooradian MJ; Villani AC; Sullivan RJ; Reynolds K; Sise ME
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1692-1700. PubMed ID: 31672794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with immune check point inhibitors and acute kidney injury.
    Valentin A; Møller AKH; Palshof JA; Broberg B; Gravesen E; Svane IM; Hansen D
    Acta Oncol; 2023 Feb; 62(2):121-125. PubMed ID: 36755491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single and combination immunotherapy with chemotherapy and the risk of AKI in patients with solid cancer.
    de Brito GA; Junior APN; Silva MBE; Bettim BB; Pereira BJ
    Clin Exp Nephrol; 2024 Apr; 28(4):273-281. PubMed ID: 37995062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.
    Koks MS; Ocak G; Suelmann BBM; Hulsbergen-Veelken CAR; Haitjema S; Vianen ME; Verhaar MC; Kaasjager KAH; Khairoun M
    PLoS One; 2021; 16(6):e0252978. PubMed ID: 34101756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge.
    Miao J; Sise ME; Herrmann SM
    Front Nephrol; 2022; 2():1017921. PubMed ID: 37674988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use.
    Min JW; Lim JU
    Semin Oncol; 2022 Apr; 49(2):141-147. PubMed ID: 35264308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.